Mogamulizumab (Poteligeo) accepted for restricted use within NHS Scotland for treatment of mycosis fungoides (MF) or Sézary syndrome (SS)

Treatment is restricted to patients with advanced MF or SS (stage ≥IIB MF and all SS) following at least one prior systemic therapy, who are clinically ineligible for or refractory to treatment with brentuximab vedotin and is supported by the NHS Scotland Patient Access Scheme.

Source:

Scottish Medicines Consortium